Porphobilinogen ( DrugBank: Porphobilinogen )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
254	ポルフィリン症	2

254. ポルフィリン症

---

臨床試験数 : 70 /  薬物数 : 54 - (DrugBank : 19) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04923516 (ClinicalTrials.gov)	June 2021	8/6/2021	Prevalence of Acute Hepatic Porphyria	Prevalence of Acute Hepatic Porphyria in Population With Suggestive Clinical Picture	Acute Hepatic Porphyria	Other: Dosage of Delta-aminolevulinic acid and Porphobilinogen	Association pour la Recherche en Medecine Interne	NULL	Not yet recruiting	18 Years	60 Years	All	500		NULL
2	NCT00418795 (ClinicalTrials.gov)	June 11, 2003	4/1/2007	Porphozym in the Treatment of Acute Attacks in AIP	A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP	Acute Intermittent Porphyria	Drug: recombinant human porphobilinogen deaminase (Porphozym)	Zymenex A/S	NULL	Completed	18 Years	N/A	All	36	Phase 2/Phase 3	United States